ProCE Banner Activity

Long-term OS Follow-up of Phase II BLAST: Blinatumomab in Adults With Ph-Negative B-Cell Precursor ALL Who Are MRD Positive

Slideset Download
Conference Coverage
Long-term OS benefit was observed in patients with Ph-negative ALL, particularly those who achieved complete MRD response after the first cycle of blinatumomab or while in first CR

Released: December 07, 2018

Expiration: December 06, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology